ArticleCureus2026
Lenacapavir-Based Salvage Therapy in Heavily Treatment-Experienced Multidrug-Resistant HIV-1: A Case Report From the United Arab Emirates.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of heavily treatment‑experienced people with HIV remains challenging due to cumulative drug resistance and limited therapeutic options. We report the case of a cisgender female with HIV‑1 subtype A1 and extensive antiretroviral therapy (ART) resistance who experienced more than a decade of suboptimal viral suppression despite multiple ART regimens. The patient accumulated resistance to all nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), all non‑nucleoside reverse transcriptase inhibitors (NNRTIs), and nearly all protease inhibitors (PIs), with limited remaining treatment options. Following virologic rebound in 2023 and failure of subsequent salvage regimens, lenacapavir was initiated in 2024 in combination with an optimized background regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The patient rapidly achieved an undetectable viral load and remains virologically suppressed to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.